Bosutinib for Chronic-Phase CML Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update


Bosutinib for Chronic-Phase CML Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Moshe Talpaz, MD (2/20/13)

Cortes JE et al. Bosutinib as therapy for chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib: 36-month minimum follow-up update. Proc ASH 2012;Abstract 3779.

Dr Talpaz is Alexander J Trotman Professor of Leukemia Research, Associate Director of Translational Research at UM Comprehensive Cancer Center, Associate Chief of the Division of Hematology/Oncology and Director of Hematologic Malignancies at the University of Michigan Medical Center in Ann Arbor, Michigan.